Zhejiang Huahai Pharmaceutical (600521.SH): HB0025 Injection Initiates Phase III Clinical Trial for Endometrial Cancer.

18:11 18/03/2026

Hua Hai Pharmaceutical Industry (600521.SH) announced that its subsidiary, Shanghai Hua Ao Tai Biopharmaceutical Co., Ltd. ("Hua Ao Tai"), will officially start the Phase III clinical trial of HB0025 injection for advanced/recurrent endometrial cancer, following communication with the Center for Drug Evaluation (CDE) of the National Medical Products Administration on the completion of Phase II clinical trials and before the start of Phase III clinical trials.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that its subsidiary Shanghai Huahangzhou Alltest Biotech Co., Ltd. ("Huaotai") has officially initiated the Phase III clinical trial of HB0025 injection for the treatment of advanced/recurrent endometrial cancer after completing Phase II clinical trials and meeting with the National Medical Products Administration's Drug Evaluation Center (CDE).

YIDU TECH (02158) spent HKD 6.554 million to repurchase 113,900 shares on March 18th.

WUXI LIFE (08148) announces a profitable year, with an expected net profit attributable to shareholders for 2025 not less than approximately 6.5 million Hong Kong dollars, turning losses into gains compared to the previous year.

XIN YUAN ENT(01748) received additional resumption guidance.

YIDU TECH (02158) spent HKD 6.554 million to repurchase 113,900 shares on March 18th.

XIN YUAN ENT(01748) received additional resumption guidance.